A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Janssen

Protocol Number
ET743-OVC-3006

To Learn More Call
201-510-0910

A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with And/Or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Type of Cancer
Ovarian Cancer

Sponsor
Pfizer

Protocol Number
B9991010

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910